This Week in Cardiology

Listener feedback, urgent AF ablation, AF ablation as a stroke-reducing therapy, implantable loop recorder accuracy, and HF management in the setting of serious disease are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Urgent AF ablations Urgent vs Elective AF Ablation in the US https://www.jacc.org/doi/10.1016/j.jacep.2025.12.030 II AF Ablation Is Not Likely a Good Therapy for Stroke Reduction STABLED Trialhttps://jamanetwork.com/journals/jamaneurology/fullarticle/2845745Catheter Ablation for AF Associated With Lower Incidence of Strokehttps://doi.org/10.1093/eurheartj/ehw087 III Loop Recorders ILR Accuracy - Multicenter, Multidevice Comparisonhttps://doi.org/10.1016/j.jacep.2025.12.039 IV Heart Failure Therapy when there is Cancer EMPATICC Trialhttps://doi.org/10.1093/eurheartj/ehaf705 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

A superb note on CPR and DNR orders, patients' vs doctors' preferences for statins, more on GLP-1s, another LAAC story, and some closing cautionary notes on PFA are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Addressing Inadequate Documentation of Unilateral DNR https://jamanetwork.com/journals/jama/fullarticle/2829203Video: Can We Talk About CPR? https://www.youtube.com/watch?v=yTCRfY3ETvIPersonal Reminiscences of CPR's Origin https://www.ajconline.org/article/S0002-9149(03)00977-9/pdf II Public Preferences for Statin Therapy Measuring Public Preferences for Statin Therapyhttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2844660 III GLP-1 RA News ACHIEVE Trialhttps://doi.org/10.1016/S0140-6736(26)00202-3 IV New Trial in GLP-1 for Patients with AF Seminal-AF Trialhttps://clinicaltrials.gov/study/NCT06499857 V Relationship between Spontaneous Echo Contrast and LAAC Outcomes OCEAN-LAAC Trialhttps://doi.org/10.1016/j.jacep.2025.09.028News Release on Upcoming LAAOS-4 trial https://www.phri.ca/watchman/Reading the "Smoke" -- Editorial on OCEAN-LAAChttps://www.jacc.org/doi/10.1016/j.jacep.2025.10.029 VI Concluding Remarks on My Talk at Western AF Delayed Myocardial Ischemia and Malignant Arrhythmias After PFAhttps://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077983 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA II DNR in the Hospital Inadequate Documentation of Unilateral DNR Ordershttps://jamanetwork.com/journals/jama/fullarticle/2829203GeriPal Blog Unilateral DNR Ordershttps://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/ III Yet another failure of Targeted Hypothermia 2-Year Follow-Up of TTM2 Trialhttps://jamanetwork.com/journals/jamaneurology/fullarticle/2845193TTM2 Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2100591 IV Good news in HFpEF Evidence ALT-FLOW II Trialhttps://doi.org/10.1093/ejhf/xuaf016 V GLP-1 as AF drugs Semaglutide as Adjunctive Therapy in Obesity-Related PAFhttps://doi.org/10.1093/europace/euag018 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Ticagrelor vs prasugrel, a new LAAC device, pulsed field ablation AF results, lifestyle intervention in AF, the term "provider" vs "doctor," and coffee are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I TUXEDO-2 Trial TUXEDO-2 Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2844869ISAR-REACT 5 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1908973 II VERITAS Study of Dual-Seal LAAO VERITAS Studyhttps://doi.org/10.1016/j.jacep.2026.01.021 III PFA vs RF over 4 years Advent-LTO studyhttps://www.nature.com/articles/s41591-026-04246-4ADVENT Studyhttps://www.nejm.org/doi/full/10.1056/NEJMoa2307291SPHERE PER-AF Studyhttps://www.nature.com/articles/s41591-024-03022-6 SINGLE SHOT CHAMPION Studyhttps://www.nejm.org/doi/full/10.1056/NEJMoa2502280BEAT PAROX-AF Trialhttps://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1115/8436829 IV What's in a Name — Use of the Term "Provider" Physicians Are Not Providers: The Ethical Significance of Nameshttps://www.acpjournals.org/doi/10.7326/ANNALS-25-03852 V Coffee and Dementia Risk Coffee/Tea Intake and Dementia Riskhttps://jamanetwork.com/journals/jama/fullarticle/2844764Mandrola Commentary: Enough With the Coffee Research and Other Distractionshttps://www.medscape.com/viewarticle/883709 VI Lifestyle interventions Post AF ablation Improving Outcomes of AF by Lifestyle Interventionshttps://academic.oup.com/eurheartj/article/47/6/669/8243674 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Problems with the PREVENT score, a breakthrough in lipid-lowering therapy, a surprising benefit in stroke care, and more thoughts on statins and preventive care of heart disease are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I PREVENT Score PREVENT Equations in Young Adultshttps://doi.org/10.1016/j.jacc.2025.12.019Hospital Readmission Reduction Program for HF https://pmc.ncbi.nlm.nih.gov/articles/PMC7664458/ II A New Breakthrough in LDL-C Management With an Oral PCSK9 Inhibitor https://www.medscape.com/viewarticle/time-overcome-pcsk9i-inertia-new-data-future-options-2025a1000wf8 CORALreef Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2511002CORALreef Outcomes Trialhttps://clinicaltrials.gov/study/NCT06008756 III A Win for the Factor XI Inhibitor Asundexian – OCEANIC Stroke Trial https://www.medscape.com/viewarticle/first-clear-win-factor-xia-inhibitors-stroke-reduced-2026a10003t0 OCEANIC-STROKE Slide deckhttps://clinicaltrialresults.org/wp-content/uploads/2026/02/26-02-02_ISC_OCEANIC-STROKE-primary.pdfOCEANIC-AF Study Stopped Earlyhttps://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/ IV Statin Side Effects Assessment of AEs Attributed to Statins -- Meta-analysishttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01578-8/fulltext N-of-1 Trial to Assess AEs of Statinshttps://www.nejm.org/doi/full/10.1056/NEJMc2031173When to Start a Statin Is a Decision About Preference -- Editorialhttps://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029808 V Heart Disease Statistics CV Statistics in the US, 2026https://www.jacc.org/doi/10.1016/j.jacc.2025.12.027 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback, huge news in the rapidly expanding world of PFA AF Ablation, obesity, and a beautiful trial studying an AI-enhanced diagnostic tool in the office are the topics discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Risk-Based TEE Omission in PVI10.1016/j.hrthm.2025.04.056 External Link II PFA News BEAT PAROX-AF trialhttps://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1115/8436829Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias Occurring After PFAhttps://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.125.077983Heart Rhythm TV: Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias https://www.youtube.com/watch?v=M-npoLKmRa4 MAUDE Adverse Event reporthttps://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=23733351&pc=QZI III Obesity trends US State-Level Obesity Trends 1990-2022 and Forecasted to 2035https://jamanetwork.com/journals/jama/fullarticle/2844495 IV New Tools in the Office TRICORDER Trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02156-7/fulltext You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback, the value of procedural volume for TAVR and MTEER, ventricular arrhythmia in older athletes, and the Goldilocks time horizon for predicting and modifying CV risk are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Procedural Volume and Outcomes for TAVI and M-TEER Operator Procedural Volumes and Outcomes for TAVR and MTEER https://jamanetwork.com/journals/jamacardiology/fullarticle/2843740 II Ventricular Arrhythmia in Older Male Endurance Athletes Myocardial Fibrosis May Raise Arrhythmia Risk in Older Male Endurance Athletes https://www.medscape.com/viewarticle/myocardial-fibrosis-may-raise-arrhythmia-risk-older-male-2026a10001y0 Timing and Relationship of VA With Exercise Patterns in Older Male Endurance Athleteshttps://doi.org/10.1093/eurjpc/zwag021 III Predicting Cardiac Risk and Statin Use 30-Year ASCVD Risk Among US Adults Aged 30-59https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012348 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Some great listener feedback, one of the best studies of the year in atrial fibrillation and heart failure, imaging to exclude left atrial thrombus, and a truly amazing first cardiac procedure are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback On Fish Oil and AF Links between omega-3 fatty acids and AF https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.058596Omega-3 and risk of AF https://doi.org/10.1016/j.pcad.2024.11.003DHA vs EPA in reducing vulnerability to AF https://www.ahajournals.org/doi/10.1161/CIRCEP.112.971515 II Withdrawal of HF Therapy AF rhythm control The AF is Gone, the EF Is Up. Can You Stop the HF Meds? https://www.medscape.com/viewarticle/af-gone-ef-can-you-stop-hf-meds-2024a1000h6o Effect of beta-blockers in patient with HF plus AF -- meta-analysishttps://pubmed.ncbi.nlm.nih.gov/25193873/TRED HF Trial10.1016/S0140-6736(18)32484-X External LinkWITHDRAW-AF Trialhttps://academic.oup.com/eurheartj/article/47/2/250/8238240 III ICE or TEE Before AF Ablation ICE vs TEE in Atrial Fibrillation Ablationhttps://jamanetwork.com/journals/jamacardiology/fullarticle/2839370 IV The Vector Procedure Percutaneous Aorto-Coronary Bypass Graft: the VECTOR procedurehttps://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.125.016130 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

The limits of knowing coronary artery disease anatomy, fish oil and AF risk, a new drug for PSVT, and maybe I was wrong about a drug for AF conversion (the RAFF4 trial). These are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Prediction of CAD is hard — even if you have anatomy CCTA in Prediction of First Coronary Events https://jamanetwork.com/journals/jama/fullarticle/2841255 II Fish Oil and AF (and as a bonus we learn again about analytic flexibility) Are Fish Oils on the Hook for AF Risk? https://www.medscape.com/viewarticle/995290 Omega-3 and Fish Oil Use With Risk of AF https://www.ahajournals.org/doi/full/10.1161/JAHA.125.043031Effect of Long-Term Marine Omega-3 Fatty Acids on the Risk of AFhttps://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055654RESPECT-EPA Trialhttps://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065520Association Between Omega-3 Fatty Acids and AF: Meta Analysishttps://link.springer.com/article/10.1007/s10557-021-07204-zFish Oil Supplements and Risk of AFhttps://academic.oup.com/eurjpc/article/29/14/1911/6679610Editorial: Fish Oil Supplements and AF Riskhttps://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057464 III A New Drug for PSVT FDA Approvalhttps://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-type-abnormally-fast-heart-rhythmRAPID trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00776-6/fulltext IV AF Conversion with Vernakalant RAFF4 Trialhttps://www.bmj.com/content/391/bmj-2025-085632.longEditorial: Rapid Cardioversion for Acute AFhttps://www.bmj.com/content/391/bmj.r2264 VI A Quick Note on HFpEF Med Op-Ed: Avalanche Survival, HFpEF Skepticism, and More https://www.medscape.com/viewarticle/med-op-ed-avalanche-survival-hfpef-skepticism-and-more-2026a1000012 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

The MI paradox of risk scores, the CELEBRATE trial of a new subcutaneous glycoprotein IIb/IIIA inhibitor (with its funny endpoint), the SURPASS CVOT trial, and the bad story of andexanet alfa are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I What do risk scores mean for individuals? Or perhaps a better question: Is a first MI preventable? Limitations of Screening in Predicting First MI https://www.jacc.org/doi/10.1016/j.jacadv.2025.102361Sudden Death Due to Cardiac Arrhythmias https://www.nejm.org/doi/abs/10.1056/NEJMra000650UMC Amsterdam group (EHJ) https://academic.oup.com/eurheartj/article/46/38/3762/8181058 II CELEBRATE Trial CELEBRATE Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268 III SURPASS CVOT Trial Published Aug 01, 2025 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1002781 SURPASS-CVOT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2505928REWIND Trial 10.1016/S0140-6736(19)31149-3 External Link IV FDA Pulls Andexanet Alfa From the Market ANNEXA 4 https://www.nejm.org/doi/10.1056/NEJMoa1814051ANNEXA I https://www.nejm.org/doi/full/10.1056/NEJMoa2313040Richard Buka Tweet https://x.com/richardbuka/status/2001045834050216327?s=20 V Mandrola's Top Cardiovascular Stories of 2025 https://www.medscape.com/viewarticle/mandrolas-top-10-cardiovascular-stories-2025-2025a1000yuh You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

An elegant study in post-TAVI atrioventricular block, a PSA for my structural colleagues, revascularization in women, and a CTO PCI trial are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I AV Block After TAVR Heart Blocks During vs After TAVR Show Distinct Patterns https://www.medscape.com/viewarticle/heart-blocks-during-vs-after-tavr-show-distinct-patterns-2025a1000ypp Mechanisms Underlying Alterations in Cardiac Conduction After TAVR https://jamanetwork.com/journals/jamacardiology/fullarticle/2842748 II Related PSA Announcement to My Structural Colleagues III Revascularization Strategies in Women with Severe Chronic CAD Women With Chronic Severe CAD Fare Better With CABG vs PCI https://www.medscape.com/viewarticle/women-chronic-severe-cad-fare-better-cabg-vs-pci-2025a1000ygd PCI vs CABG in Women With Chronic CAD https://doi.org/10.1093/eurheartj/ehaf806PCI vs CABG - Meta-Analysis of 4 RCTs https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02334-5/abstractCABG vs Drug-Eluting Stent Implantation for CAD - Meta-Analysis https://www.jacc.org/doi/10.1016/j.jcin.2016.10.008RECHARGE trial https://therechargetrial.com/ IV A CTO PCI RCT – But don't get your hopes up Early vs Late-Staged PCI After Subintimal Tracking and Re-entry for CTO https://doi.org/10.1016/j.jacc.2025.09.1598DECISION CTO trial https://pubmed.ncbi.nlm.nih.gov/30813758/National Inpatient Sample Database PCI CTO Associated With Higher Mortality https://pubmed.ncbi.nlm.nih.gov/37356643/ V Mandrola's Top 10 Stories You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Less is more after PCI, the TARGET-FIRST trial, a negative blood pressure trial that is actually positive, aspirin vs OAC for bleeding, AEDs, and Factor XI is not dead yet are the topics discussed by John Mandrola, MD, on this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Less is More: TARGET-FIRST TARGET-FIRST Trial https://www.nejm.org/doi/10.1056/NEJMoa2508808STOPDAPT-2 ACS Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2789701 II A Negative Trial That Is Actually Positive The RETREAT-FRAIL Study https://www.nejm.org/doi/full/10.1056/NEJMoa2508157 III Major Bleeding With Aspirin vs Apixaban Subanalysis of ARTESiA https://jamanetwork.com/journals/jamacardiology/fullarticle/2841075ARTESiA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2310234AVERROES Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1007432 IV High Value Interventions – The AED Experts Call for AED Placement on All Commercial Aircraft https://www.medscape.com/viewarticle/experts-call-aed-placement-all-commercial-aircraft-2025a1000xzf In-Flight Sudden Cardiac Arrest and AED Use 10.1016/j.cjca.2025.10.010 External Link V Factor XI Inhibitors – OCEANIC STROKE trial Bayer Press Release on Asundexian https://www.bayer.com/en/us/news-stories/oceanic-stroke You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback, huge news in the world of carotid disease with the CREST-2 publication, prasugrel beats ticagrelor again, and a big coffee trial are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Complete Revascularization for Acute MI Meta-analysis https://doi.org/10.1016/S0140-6736(25)02170-1 II A Sea Change in the Treatment of Carotid Artery Disease — CREST-2 Published ECST-2 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00107-3/fulltextSPACE-2 https://pubmed.ncbi.nlm.nih.gov/36115360/CREST-2 Trial www.nejm.org/doi/full/10.1056/NEJMoa2508800CREST Protocol paper https://pmc.ncbi.nlm.nih.gov/articles/PMC5987521/ III Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt PLATO trial https://www.nejm.org/doi/full/10.1056/NEJMoa0904327Ticagrelor or prasugrel vs clopidogrel in PCI https://eurointervention.pcronline.com/article/ticagrelor-or-prasugrel-versus-clopidogrel-in-patients-undergoing-percutaneous-coronary-intervention-for-chronic-coronary-syndromesISAR-REACT 5 trial https://www.nejm.org/doi/full/10.1056/NEJMoa1908973 IV Another Coffee and AF study Can Coffee Cut the Risk for Atrial Fibrillation? https://www.medscape.com/viewarticle/can-coffee-cut-risk-atrial-fibrillation-2025a1000w11 A Coffee a Day to Keep the AFib Away? The DECAF Trial Discussed https://www.medscape.com/viewarticle/coffee-day-keep-afib-away-decaf-trial-discussed-2025a1000v5z DECAF trial https://jamanetwork.com/journals/jama/fullarticle/2841253 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback on the PISCES trial, AHA news (including a big PCSK9i trial), beta-blockers post MI, LAAC, and post-AF ablation OAC use are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Why I Believe Fish Oil's Big CV Benefit in Dialysis Patients https://www.medscape.com/viewarticle/why-i-believe-fish-oils-big-cv-benefit-dialysis-patients-2025a1000uzg PISCES trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513032 II PCSK9 Inhibitor News In Global Trial, PCSK9 Inhibitor Provides Major Protection Against First CV Event https://www.medscape.com/viewarticle/global-trial-pcsk9-inhibitor-provides-major-protection-2025a1000uzp VESALIUS-CV trial https://www.nejm.org/doi/full/10.1056/NEJMoa2514428ODYSSEY trial https://www.nejm.org/doi/full/10.1056/NEJMoa1801174FOURIER https://www.nejm.org/doi/full/10.1056/NEJMoa1615664Anish Koka Tweet on LDL-lowering https://x.com/anish_koka/status/1987280506937909326?s=20 III Beta-Blockers After MI and John Cleland Beta-Blockers after MI with normal EF https://www.nejm.org/doi/full/10.1056/NEJMoa2512686REBOOT-CNIC trial https://www.nejm.org/doi/full/10.1056/NEJMoa2504735REDUCE AMI trial https://academic.oup.com/ehjcvp/article/9/2/192/6895544?login=falseABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204CAPITAL RCT trial https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199347Beta-Blockers after MI with mildly reduced EF https://pubmed.ncbi.nlm.nih.gov/40897190/John Cleland Clinical Outlook https://www.nature.com/articles/s41569-025-01228-w IV Left Atrial Appendage Closure – The CLOSURE-AF trial Percutaneous LAAC in AF Falls Short Again in CLOSURE-AF https://www.medscape.com/viewarticle/percutaneous-left-atrial-appendage-closure-af-falls-short-2025a1000uzu Prague-17 Trialhttps://www.jacc.org/doi/10.1016/j.jacc.2020.04.067OPTION trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2408308 V Oral AC after AF ablation – the OCEAN Trial Anticoagulation After AF Ablation: The OCEAN Trial Still Leaves Questions https://www.medscape.com/viewarticle/anticoagulation-after-af-ablation-ocean-trial-still-leaves-2025a1000v4t OCEAN Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2509688ALONE-AF trialhttps://jamanetwork.com/journals/jama/fullarticle/2838294 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback on non-culprit PCI in STEMI, a major cardiac result in patients on hemodialysis, news on GLP-1 agonists, a dubious stroke trial, and an AHA preview are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Meta-analysis of MI as a surrogatehttps://pubmed.ncbi.nlm.nih.gov/34694318/Compare Acute Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1701067DANAMI-3–PRIMULTI10.1016/S0140-6736(15)60648-1 External LinkCULPRIT-SHOCKhttps://www.nejm.org/doi/full/10.1056/NEJMoa1710261 II Huge Cardiac News for Patients with ESRD PISCES article EMBARGOED Till 1130 AM EST PISCES Trialwww.nejm.org/doi/full/10.1056/NEJMoa2513032REDUCE-IT Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1812792STRENGTH Trialhttps://jamanetwork.com/journals/jama/fullarticle/2773120FISH trialhttps://jamanetwork.com/journals/jama/fullarticle/1150094 III Obesity Agents White House announces deal with Lilly and Novo on GLP-1 drugshttps://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-shares-rise-trump-obesity-drug-deal-nears-2025-11-06/ Amylin Agonists Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf Eloralintide Phase 2 Studyhttps://doi.org/10.1016/S0140-6736(25)02155-5 GLP-1 Comparisons SURMOUNT-5 Trialhttps://www.nejm.org/doi/10.1056/NEJMoa2416394Tirzepatide vs Semaglutide in 10-year CVD Risk Reductionhttps://doi.org/10.1093/ehjopen/oeaf117 IV A Problematic Trial in Stroke Care LAMP trialhttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2840370 V AHA Preview AHA 2025: Mandrola's Four Trials to Look For https://www.medscape.com/viewarticle/aha-2025-mandrolas-four-trials-look-2025a1000u80 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Four pillars of cardiology today, stable coronary artery disease, severe aortic stenosis, the evaluation of chest pain, and best therapies for atrial fibrillation are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Stable CAD Complete vs culprit-only revascularization at time of STEMI iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918PRAMI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1305520COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149PCI Revascularization Strategies After MI https://www.jacc.org/doi/10.1016/j.jacc.2024.04.051CULPRIT SHOCK Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1710261How a Meta-Analysis Can Mislead https://www.sensible-med.com/p/how-a-meta-analysis-can-misleadthe II SEVERE Aortic Senosis 7-Year PARTNER 3 Results – TAVI vs SAVR 7-year results PARTNER 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2509766PARTNER 3 at 1 year https://www.nejm.org/doi/10.1056/NEJMoa1814052PARTNER 3 at 5 years https://www.nejm.org/doi/10.1056/NEJMoa2307447 III Functional vs Anatomic Assessment in Suspected CAD 10-year follow-up of PROMISE trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2838118PROMISE Trial https://www.nejm.org/doi/10.1056/NEJMoa1415516CCTA vs Functional Stress Test – Meta-Analysis https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2655243 IV ARREST AF ARREST AF trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2840225 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

The PREVENT score in hypertension, GLP-1 mechanism of action in cardiovascular disease, CAD type and statin benefit, and the problem with hospitalization endpoints in HF trials are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Is the PREVENT Calculator Best for Determining CVD Risk? Insights From a Post Hoc Analysis of SPRINT Trial https://www.medscape.com/viewarticle/prevent-calculator-best-determining-cvd-risk-insights-post-2025a1000svo PREVENT Calculator https://doi.org/10.1016/j.jacc.2025.07.037SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939 II GLP-1 Mechanism of Action in CV Disease Analysis of SELECT Trial10.1016/S0140-6736(25)01375-3 External LinkSELECT trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2307563 III Statins and CAD Phenotype on CTA and Outcomes Interactions Between Statin Use, CAD Phenotypes on CTA https://www.jacc.org/doi/10.1016/j.jcmg.2025.05.018Statin Use for Primary Prevention of CVDhttps://jamanetwork.com/journals/jama/fullarticle/2795522 IV HHF Endpoints in Heart Failure Trials The Problem with Hospitalization Endpoints in HF Trialshttps://onlinelibrary.wiley.com/doi/10.1002/ejhf.70070 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Another knock against the antiplatelet/anticoagulant combo, polypills in HF, the physical exam of the future, and the problem of underpowered trials that even Bayesian analyses cannot rescue are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Trends Studyhttps://www.heartrhythmjournal.com/article/S1547-5271(11)00496-6/fulltext II Another knock against the Antiplatelet/Anticoagulation combination “Antiplatelet Plus Oral Anticoagulant Lowers Stroke, Raises Bleeding Risk” https://www.medscape.com/viewarticle/antiplatelet-plus-oral-anticoagulant-lowers-stroke-raises-2025a1000re0 ATIS-NVAF Trialhttps://jamanetwork.com/journals/jamaneurology/fullarticle/2839511AQUATIC trialhttps://www.nejm.org/doi/abs/10.1056/NEJMoa2507532 III Polypill for HFrEF A Multilevel Polypill for Patients With HFrEFhttps://www.jacc.org/doi/10.1016/j.jacadv.2025.102195 IV The Physical Exam of the Future Point-of-Care Ultrasoundhttps://doi.org/10.1016/j.jchf.2025.102707 V More on Underpowered Trials – GA vs Moderate Sedation in IV stroke SEGA Trialhttps://jamanetwork.com/journals/jamaneurology/fullarticle/2839838Bayesian Analyses of CV Trialshttps://doi.org/10.1016/j.cjca.2021.03.014 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

GLP-1 use in HFrEF, left atrial posterior wall isolation during AF ablation, peri-device leaks for LAAO, new findings in post-cardiac surgery AF, and imaging before AF ablation are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Listener Feedback HYPERION trial https://www.nejm.org/doi/10.1056/NEJMoa2508170 ZENITH trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160 II GLP1 Use in HFrEF Effects of GLP-1s in Patients With HFrEF https://doi.org/10.1016/j.jchf.2025.102573 FIGHT Study https://jamanetwork.com/journals/jama/fullarticle/2540402 FIGHT Study Post-hoc Analysis https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14862 Substudy of EXSCEL Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.041659 III LA Posterior Wall Isolation Saga Failure of PW Wall Isolation by PFA with Epicardial Mapping https://doi.org/10.1016/j.jacep.2025.08.017 IV Peridevice Leaks After LAAO IMPRESSION LAAC Study https://doi.org/10.1016/j.jacep.2025.08.014 V Post Cardiac Surgery AF Monitoring of New-Onset AF After CABG https://jamanetwork.com/journals/jama/fullarticle/2839710 PACES trial https://clinicaltrials.gov/study/NCT04045665 VI TEE vs ICE Before AF ablation ICE vs TEE Study https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Two great stories of translation science leading to beneficial drugs in terrible diseases of the heart and the Sisyphean task of predicting the need for pacing after TAVI are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Sotatercept HYPERION Trial https://www.nejm.org/doi/10.1056/NEJMoa2508170ZENITH Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160Evidence report on treatment for PAH https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-on-treatment-for-pulmonary-arterial-hypertension/PAH Sotatercept Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2503944 II Acoramidis and ATTR Cardiomyopathy ATTRIBUTE-CM Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2305434?logout=trueATTRIBUTE-CM Analysis - Substudy https://www.jacc.org/doi/10.1016/j.jacc.2025.09.013Tafamadis Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1805689 III Pacing After TAVI Prophylactic pacemaker after TAVI https://www.jacc.org/doi/10.1016/j.jacep.2025.07.028PROMOTE study https://doi.org/10.1016/j.hrthm.2024.12.019Evaluation of ESC criteria on RBBB patients undergoing TAVI https://doi.org/10.1016/j.hrthm.2024.11.030Editorial on Heart Rhythm journal papers https://www.heartrhythmjournal.com/article/S1547-5271(25)00114-6/abstract You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net